Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 10/20 | 0.64 |
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR1F | P30939 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 5/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437753 | 0.89 | UTS2R (0.58) | UTS2RDRD2HTR1ACYP2D6HTR1D | |
| SCHEMBL12437765 | 0.87 | BCHE (0.59) | UTS2RDRD2DRD4DRD3 | |
| SCHEMBL12437606 | 0.87 | DRD2 (0.57) | UTS2RDRD2DRD4MCHR1 | |
| SCHEMBL12437757 | 0.84 | BCHE (0.53) | UTS2RDRD2DRD4DRD3 | |
| SCHEMBL12437745 | 0.84 | UTS2R (0.59) | UTS2R | |
| SCHEMBL2389013 | 0.83 | UTS2R (0.71) | UTS2RCYP2D6DRD4MCHR1 | |
| SCHEMBL12437948 | 0.82 | SLC5A7 (0.56) | UTS2RMCHR1 | |
| SCHEMBL2214246 | 0.82 | EPHX2 (0.55) | UTS2R | |
| SCHEMBL12437947 | 0.81 | SLC5A7 (0.56) | — | |
| SCHEMBL12437957 | 0.81 | SLC5A7 (0.51) | DRD2CYP2D6DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | UTS2R 854/4885DRD2 1842/4885HTR1A 3457/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | UTS2R 854/4885DRD2 1842/4885HTR1A 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.